Pediatr Hematol Oncol 2004 Jun;21(4):307-11
Department of Pediatric Hematology, Oncology and Immunology, University Medical Center, Heinrich-Heine-University, Düsseldorf, Germany.
In most pediatric tumors, particularly sarcomas, cyclophosphamide or ifosfamide represent essential first-line chemotherapeutic agents. Whereas cyclophosphamide is known to be associated with a well-defined cardiomyopathy, only a few cardiac complications following ifosfamide chemotherapy have been observed to date. Here we report a patient treated for Ewing sarcoma with multiple pulmonary and osseous metastases who repeatedly developed a supraventricular tachyarrhythmia following administration of ifosfamide as part of a polychemotherapy regimen.